Developmental reprogramming of myometrial stem cells by endocrine disruptor linking to risk of uterine fibroids. Yang Q, Ali M, Trevino L, Mas A, Al-Hendy A. Cellular and Molecular Life Sciences. 2023 Aug 31;80(9):274. doi: 10.1007/s00018-023-04919-0. PMID: 37650943

The human periconceptional maternal-embryonic space in health and disease. Moreno I, Capalbo A, Mas A, Garrido-Gomez T, Roson B, Poli M, Dimitriadis E, Santamaria X, Vilella F, Simon C. Physiological Reviews. 2023 Jul 1;103(3):1965-2038. doi: 10.1152/physrev.00050.2021. PMID: 36796099

Uterine leiomyoma with RAD51B:NUDT3 fusion: a report of 2 cases. Dundr P, Machado-Lopez A, Mas A, Veckova Z, Mara M, Richtarova A, Matej R, Struzinska I, Bartu M, Nemejcova K, Dvorak J, Hojny J. Virchows Archiv. 2023 Jul 19. doi: 10.1007/s00428-023-03603-9. PMID: 37466765

Integrative genomic and transcriptomic profiling reveals a differential molecular signature in uterine leiomyoma versus leiomyosarcoma. Machado Lopez A, Alonso R, Lago V, Jimenez Almazan J, Garcia M, Monleon J, Lopez S, Barcelo F, Torroba A, Ortiz S, Domingo S, Simon C, Mas A. International Journal of Molecular Sciences. 2022 Feb 16;23(4):2190. doi: 10.3390/ijms23042190. PMID: 35216305

Molecular Management of High-Grade Serous Ovarian Carcinoma. Punzon-Jimenez P, Lago V, Domingo S, Simon C, Mas A. International Journal of Molecular Sciences. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777. PMID: 36430255